Eye drops redefined

An eye for innovation in eye care


Administering topical eye medication is a massive challenge for patients in particular for seniors and children, but also for all other age groups. This potentially results in poor treatment outcomes, low compliance, blindness and poor quality of life.

EYE-GO is an international development stage company, with focus on solving the above issues by use of innovative device technology

PATIENTS and casual users also experience DIFFICULTIES with the eye drop bottle

Difficult to aim / Difficult to squeeze / Overdosing – every time / Adverse events





Only 10% of glaucoma patients are treatment compliant

Approx. 120.000 Americans are blind from glaucoma

Non compliance causes blindness

We have a solution



Precise dosing through a mist technology

Precise delivery of the medication

Easy to handle device – even with low dexterity

Preservative free formulations

Range of viscosities

Increase compliance


EYE-GO Closes major investment round with existing investors and Maj Invest Holding, one of the most successful capital funds in Denmark.

EYE-GO partners up with DTU on Master Project in a virgin field of research within ophthalmology

2019/10 new CEO take over leadership of company. 20+ years of international management experience in world-leadning Life Science companies. Focused on bringing medical devices from idea to market in the fastest and most efficient way. Previous roles includes VP in Coloplast and Ambu

EYE-GO patents have been granted in US and Europe. New patents submitted and new, international customer in place

Strong team in medical devices

We work together as one team of people with expertise and determination to achieve our goals collectively. Our values of respect, trust, and appreciation are at the very core of our foundation.


Henrik NagelCEO
M.: +45 9398 9339
Executive Board
Ole FeddersenBoard member
Novo Nordisk
Joachim VanggaardBoard member
Maj Invest Holding
Christian Stig MoellerBoard Chairman
GM Fisher Investments
Bent JohnsenCommercial
Ex- Novo Nordisk, PNL
Kurt SolgaardDevelopment Engineering

DTU – Technical University of Denmark – Institute for Mechanical Engineering

Rigshospitalets Øjenafdeling (National Hospital of Denmark, Ophthalmic ward and research unit)